Fedorko Michal, Stanik Michal, Iliev Robert, Redova-Lojova Martina, Machackova Tana, Svoboda Marek, Pacik Dalibor, Dolezel Jan, Slaby Ondrej
Department of Urology, University Hospital Brno and Masaryk University Brno, Brno 62500, Czech Republic.
Department of Urologic Oncology, Masaryk Memorial Cancer Institute, Brno 65653, Czech Republic.
Int J Mol Sci. 2015 Sep 29;16(10):23382-9. doi: 10.3390/ijms161023382.
Serum microRNAs are emerging as a clinically useful tool for early and non-invasive detection of various cancer types including renal cell carcinoma (RCC). Based on our previous results, we performed the study to analyze circulating serum miR-378 and miR-210 in patients with various histological subtypes of RCC. RNA was purified from blood serum samples of 195 RCC patients and 100 healthy controls. The levels of miR-378 and miR-210 in serum were determined absolutely using quantitative real-time PCR. Pre- and postoperative levels of both microRNAs were compared in 20 RCC patients. Significantly increased serum levels of both miR-378 and miR-210 enabled to clearly distinguish RCC patients and healthy controls with 80% sensitivity and 78% specificity if analyzed in combination (p<0.0001), and their levels significantly decreased in the time period of three months after radical nephrectomy (p<0.0001). Increased level of miR-378 positively correlates with disease-free survival (p=0.036) and clinical stage (p=0.0476). The analysis of serum miR-378 and miR-210 proved their potential to serve as powerful non-invasive diagnostic and prognostic biomarkers in RCC.
血清微小RNA正成为一种临床上有用的工具，用于包括肾细胞癌（RCC）在内的各种癌症类型的早期和非侵入性检测。基于我们之前的研究结果，我们开展了这项研究，以分析不同组织学亚型RCC患者循环血清中的miR-378和miR-210。从195例RCC患者和100例健康对照者的血清样本中提取RNA。使用定量实时PCR绝对定量测定血清中miR-378和miR-210的水平。比较了20例RCC患者术前和术后这两种微小RNA的水平。如果联合分析，miR-378和miR-210血清水平显著升高能够以80%的敏感性和78%的特异性清晰区分RCC患者和健康对照者（p<0.0001），并且在根治性肾切除术后三个月内其水平显著下降（p<0.0001）。miR-378水平升高与无病生存期（p=0.036）和临床分期（p=0.0476）呈正相关。血清miR-378和miR-210分析证明了它们作为RCC强大的非侵入性诊断和预后生物标志物的潜力。
